Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
0.8918
+0.0415 (4.88%)
At close: Jun 22, 2026, 4:00 PM EDT
0.8650
-0.0268 (-3.01%)
Pre-market: Jun 23, 2026, 7:40 AM EDT
Traws Pharma Revenue
Traws Pharma had revenue of $2.73M in the twelve months ending March 31, 2026, up 1,103.96% year-over-year. In the year 2025, Traws Pharma had annual revenue of $2.79M with 1,134.51% growth.
Revenue (ttm)
$2.73M
Revenue Growth
+1,103.96%
P/S Ratio
4.94
Revenue / Employee
$390,429
Employees
7
Market Cap
13.51M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.79M | 2.56M | 1,134.51% |
| Dec 31, 2024 | 226.00K | - | - |
| Dec 31, 2023 | 226.00K | - | - |
| Dec 31, 2022 | 226.00K | - | - |
| Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
| Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
| Dec 31, 2019 | 2.18M | 955.00K | 77.77% |
| Dec 31, 2018 | 1.23M | 441.00K | 56.04% |
| Dec 31, 2017 | 787.00K | -4.76M | -85.81% |
| Dec 31, 2016 | 5.55M | -5.91M | -51.59% |
| Dec 31, 2015 | 11.46M | 10.66M | 1,332.00% |
| Dec 31, 2014 | 800.00K | -3.95M | -83.17% |
| Dec 31, 2013 | 4.75M | -41.44M | -89.71% |
| Dec 31, 2012 | 46.19M | 44.70M | 3,006.25% |
| Dec 31, 2011 | 1.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| OSR Holdings | 2.63M |
| Cyclerion Therapeutics | 1.99M |
| SeaStar Medical Holding | 1.44M |
| BioLineRx | 1.40M |
| CytoMed Therapeutics | 669.28K |
| Lexaria Bioscience | 368.00K |
| Cocrystal Pharma | 225.00K |
TRAW News
- 1 day ago - Traws Pharma provides update on tivoxavir marboxil program - TheFly
- 1 day ago - Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program - GlobeNewsWire
- 5 days ago - Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 8 days ago - Traws Pharma downgraded to Neutral from Buy at Ladenburg - TheFly
- 10 days ago - Traws Pharma influenza challenge study deferred following MHRA review - TheFly
- 10 days ago - Traws Pharma Provides Regulatory Update on Influenza Program - GlobeNewsWire
- 25 days ago - Traws Pharma Proxy statement: Proxy filing - Filings
- 25 days ago - Traws Pharma Proxy statement: Proxy filing - Filings